PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Michael R. Bishop, MD - Betting on CAR-T Cell Therapy: Expert Perspectives on Effective Integration Strategies and Achieving Improved Outcomes Across Hematologic Cancers
Go online to PeerView.com/MSF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in hematologic oncology will deliver guidance on the latest safety and efficacy data regarding the use of CAR-T therapy in settings such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and chronic lymphocytic leukemia. Panelists will draw on their personal anecdotes and intra-institutional experiences to illustrate best practices for effectively incorporating cellular therapies into treatment plans while addressing practicalities of care, such as timely referral to specialized centers, management of unique adverse events, longer-term follow-up, and eligibility for enrollment in clinical trials testing the next steps with CAR-T therapy. Upon completion of this activity, participants should be better able to: Discuss up-to-date efficacy and safety evidence on adoptive immunotherapy with chimeric antigen receptor (CAR)-T cells in leukemia and lymphoma, Analyze the role and benefits of CAR-T cell therapy in the treatment of patients with leukemia and lymphoma, particularly in patients eligible for clinical trials, Integrate approved and emerging CAR-T cell therapies into treatment plans in a safe and effective manner, including by referring patients to specialized centers and effectively managing unique adverse events.